[Skip to Navigation]
Sign In
Comment & Response
December 2018

Pacritinib in Patients With Myelofibrosis

Author Affiliations
  • 1Teikyo University Chiba Medical Center, Chiba, Japan
  • 2Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan
JAMA Oncol. 2018;4(12):1786-1787. doi:10.1001/jamaoncol.2018.4830

To the Editor In the phase 3 PERSIST-2 study reported by Mascarenhas et al,1 a Janus kinase 2 (JAK2) inhibitor, pacritinib, was more effective than best available therapy (BAT), including a JAK1 and JAK2 inhibitor, ruxolitinib, for reducing the size of the spleen and subjective symptoms in patients with myelofibrosis who had intermediate- or high-risk disease and moderate to severe thrombocytopenia. We have several concerns about this randomized clinical trial.

Add or change institution